Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
In a 72-week trial studying Zepbound (tirzepatide 15 mg), the average weight loss was approximately 20%
Highest dose, obesity trial obesity-plus-diabetes trial (treatment-policy estimand): Semaglutide: 14.9% (STEP 1) 9.6% (STEP 2), a 5.3 point gap Tirzepatide: 20.9% (SURMOUNT-1) 14.7% (SURMOUNT-2), a 6.2 point gap Retatrutide: 25.0% (TRIUMPH-1) 20.8% (TRIUMPH-2 only efficacy-estimand currently reported so true gap is larger) It's still unclear the reason why we observe less weight loss in those with T2D
Semaglutide GLP-1 is a medication that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist
Official communication about our medicines containing semaglutide from Novo Nordisk This site is intended for a US audience Latest on compounded and counterfeit products and other important information about semaglutide Latest on compounded and counterfeit products and other semaglutide information Patient safety is our top priority, and we are concerned about unapproved compounded semaglutide exposing patients to serious safety and efficacy risks
US$ 25.29
US$ 20.03
US$ 21.27
US$ 22.78
US$ 23.46
US$ 24.79
